Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why I'm Considering Leaning Heavily Into Pfizer


High-yield dividend stocks have long been a cornerstone of wealth-building strategies for savvy investors. Typically offering yields above 3%, these companies have consistently outperformed the S 500 over extended time frames when dividends are diligently reinvested. This outperformance stems from the powerful combination of accelerated compounding and the tendency for high-yield stocks to be temporarily undervalued.

Pharmaceutical-powerhouse (NYSE: PFE) has recently emerged as an intriguing candidate in the high-yield category. The drugmaker's stock price has taken a significant hit, tumbling over 30% in the past 36 months. This substantial decline has pushed its dividend yield to an attractive 5.73% at current levels, well above its historical average of approximately 3.3%.

Image source: Getty Images.

Continue reading


Source Fool.com

Pfizer Inc. Stock

€23.14
1.650%
There is an upward development for Pfizer Inc. compared to yesterday, with an increase of €0.38 (1.650%).
With 15 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 29 € there is a positive potential of 25.35% for Pfizer Inc. compared to the current price of 23.14 €.
Like: 0
PFE
Share

Comments